Review
Oncology
Juan Carlos Lopez-Gil, Laura Martin-Hijano, Patrick C. Hermann, Bruno Sainz Jr
Summary: This review summarizes the role of CXCL12 and its receptors in cancer stem cells and their niche, discusses therapeutic options, and highlights the need for a comprehensive review on the topic.
Review
Biochemistry & Molecular Biology
Yaru Yang, Jiayan Li, Wangrui Lei, Haiying Wang, Yunfeng Ni, Yanqing Liu, Huanle Yan, Yifan Tian, Zheng Wang, Zhi Yang, Shulin Yang, Yang Yang, Qiang Wang
Summary: Cancer is a complex disease caused by genetic mutations and/or epigenetic changes, and it poses the biggest challenge worldwide. Cytokines, particularly chemokines, play a significant role in various human cancers by affecting homeostasis, immune function, and facilitating cancer development stages such as invasion, metastasis, and angiogenesis. Specifically, chemokines such as CXCL12 and its receptors CXCR4 and CXCR7 exert extensive influence on tumor cell behavior, including proliferation, survival, angiogenesis, metastasis, and tumor microenvironment, making them crucial players in the initiation and progression of cancers such as leukemia, breast cancer, lung cancer, prostate cancer, and multiple myeloma. This review aims to summarize the recent research progress and future challenges related to the CXCL12-CXCR4/CXCR7 signaling axis in cancer, emphasizing the potential of utilizing CXCL12-CXCR4/CXCR7 as a biomarker or therapeutic target for cancer treatment and providing valuable insights for the development of targeted cancer therapies.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Isabel Heidegger, Georgios Fotakis, Anne Offermann, Jermaine Goveia, Sophia Daum, Stefan Salcher, Asma Noureen, Hetty Timmer-Bosscha, Georg Schaefer, Annemiek Walenkamp, Sven Perner, Aleksandar Beatovic, Matthieu Moisse, Christina Plattner, Anne Krogsdam, Johannes Haybaeck, Sieghart Sopper, Stefanie Thaler, Markus A. Keller, Helmut Klocker, Zlatko Trajanoski, Dominik Wolf, Andreas Pircher
Summary: This study provides a comprehensive analysis of prostate cancer tumor endothelial cells (TEC) and identifies potential therapeutic targets, specifically the CXCL12/CXCR4 interaction, to interfere with tumor angiogenesis in prostate cancer. Understanding the cell-to-cell communication networks in the tumor microenvironment contributes to the development of new therapeutic approaches for prostate cancer.
Article
Oncology
Tomokatsu Kato, Yoichi Matsuo, Goro Ueda, Hiromichi Murase, Yoshinaga Aoyama, Kan Omi, Yuichi Hayashi, Hiroyuki Imafuji, Kenta Saito, Mamoru Morimoto, Ryo Ogawa, Hiroki Takahashi, Shuji Takiguchi
Summary: The study found that CXCR4 is highly expressed in radiation-resistant PaCa cells, and the CXCL12/CXCR4 axis may be involved in the radiation resistance of PaCa. Treatment with a CXCR4 antagonist can suppress the invasion ability of radiation-resistant PaCa cells, aiding in the inhibition of cell colonization.
Review
Biochemistry & Molecular Biology
Tripti Khare, Marc Bissonnette, Sharad Khare
Summary: Chemokines like CXCL12 play a significant role in cancer growth and metastasis, with receptors like CXCR4 and CXCR7 being potential targets for treatment strategies in colorectal cancer. Targeting the CXCL12-CXCR4/CXCR7 axis shows promise in developing new therapies for CRC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Ruozheng Wei, Yuning Zhou, Chang Li, Piotr Rychahou, Shulin Zhang, William B. Titlow, Greg Bauman, Yuanyuan Wu, Jinpeng Liu, Chi Wang, Heidi L. Weiss, B. Mark Evers, Qingding Wang
Summary: This study identifies ketogenesis as a critical regulator of the tumor microenvironment in colorectal cancer and suggests the potential for ketogenic diets as a metabolic strategy to overcome immunosuppression and prolong survival.
Article
Endocrinology & Metabolism
Francesca Coperchini, Alessia Greco, Laura Croce, Elena Petrosino, Beatrice Grillini, Flavia Magri, Luca Chiovato, Mario Rotondi
Summary: Vitamin D treatment reduces cell migration and inhibits the secretion of CCL2 and CXCL8 in thyroid cancer cells. This study reveals the significant role of vitamin D in thyroid cancer progression.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Medicine, Research & Experimental
Mei Zheng, Sang Ho Oh, Nahyun Choi, Yong Jin Choi, Jino Kim, Jong-Hyuk Sung
Summary: This study reveals that CXCL12 inhibits hair growth through the CXCR4/STAT signaling pathway, and inhibitors of the CXCL12/CXCR4 pathway show promise as a treatment option for hair growth.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Yan Qin, Fang Wang, Hengli Ni, Yao Liu, Yuan Yin, Xinyi Zhou, Guihua Gao, Qing Li, Xiaowei Qi, Jianming Li
Summary: This study found that high expression of CXCL12 in CAFs in the gastric cancer TME can enhance the migration, invasion, and EMT of GC cells, leading to poor prognosis in patients with GC.
Article
Oncology
Shivani Malik, Jill M. Westcott, Rolf A. Brekken, Francis J. Burrows
Summary: Pancreatic cancer is a challenging disease with limited therapeutic options and poor long-term survival. This review focuses on the role of a chemokine called CXCL12, secreted by cancer-associated fibroblasts, in promoting various hallmarks of pancreatic cancer such as tumor growth and evasion of immune response. Different approaches to target CXCL12 signaling are discussed, and a novel approach using a farnesyl transferase inhibitor called tipifarnib to inhibit CXCL12 production in pancreatic fibroblasts is proposed.
Review
Biochemistry & Molecular Biology
Mayara Bocchi, Nathalia de Sousa Pereira, Karen Brajao de Oliveira, Marla Karine Amarante
Summary: Migration of metastatic tumor cells is similar to the traffic of leukocytes and can be guided by chemokines and their receptors. The CXCL12/CXCR4 axis plays a crucial role in hematopoietic stem cell homing and supports malignant events. This axis serves as a communication bridge between tumor-stromal cells, creating a favorable microenvironment for tumor development, angiogenesis, and metastasis. This review explores the correlation between the CXCL12/CXCR4 axis and colorectal cancer, as well as potential therapeutic strategies.
MOLECULAR BIOLOGY REPORTS
(2023)
Article
Cell Biology
Xue Wu, Lu Qian, Huadong Zhao, Wangrui Lei, Yanqing Liu, Xiaoling Xu, Jiawen Li, Zhi Yang, Du Wang, Yuchen Zhang, Yan Zhang, Ran Tang, Yang Yang, Ye Tian
Summary: Fibrosis is a pathological process caused by abnormal wound healing response, leading to excessive deposition of extracellular matrix, distortion of organ architecture, and loss of organ function. CXCL12/CXCR4 play various roles in the pathological mechanisms of fibrosis and have been shown to improve fibrosis levels in multiple organs.
AGEING RESEARCH REVIEWS
(2023)
Review
Pharmacology & Pharmacy
Ruogang Zhao, Jianhao Liu, Zhaohuan Li, Wenhui Zhang, Feng Wang, Bo Zhang
Summary: This review focuses on the mechanisms of the CXCL12/CXCR4 axis, the use of CXCL12/CXCR4 antagonists, and the application of nano-based drug delivery systems targeting the biological axis.
Article
Oncology
Manqi Zhang, Yasemin Ceyhan, Shenglin Mei, Taghreed Hirz, David B. Sykes, Irina U. Agoulnik
Summary: Prostate cancer is driven by multiple genetic alterations, and the loss of INPP4B and PTEN is a common tumor suppressor loss in prostate cancer. The loss of INPP4B and PTEN triggers different compensatory responses in prostate tissue.
Article
Genetics & Heredity
Wei Guan, Fan Li, Zhenyu Zhao, Zongbiao Zhang, Junhui Hu, Yan Zhang
Summary: The study found that TAM activates CXCR4 by increasing secreted CXCL12, enhancing the survival of cancer cells and elucidating the mechanism of TAM in chemotherapy. This finding may aid in the development of new drugs to overcome immune tolerance in castration-resistant prostate cancer.
Editorial Material
Oncology
Mark Lawler, Anna Gavin, Manuel Salto-Tellez, Richard D. Kennedy, Sandra Van Schaeybroeck, Richard H. Wilson, Denis Paul Harkin, Margaret Grayson, Ruth E. Boyd, Peter W. Hamilton, Darragh G. McArt, Jacqueline James, Tracy Robson, Robert D. Ladner, Kevin M. Prise, Joe M. O'Sullivan, Timothy Harrison, Liam Murray, Patrick G. Johnston, David J. Waugh
Article
Oncology
Philip D. Dunne, Darragh G. McArt, Conor A. Bradley, Paul G. O'Reilly, Helen L. Barrett, Robert Cummins, Tony O'Grady, Ken Arthur, Maurice B. Loughrey, Wendy L. Allen, Simon S. McDade, David J. Waugh, Peter W. Hamilton, Daniel B. Longley, Elaine W. Kay, Patrick G. Johnston, Mark Lawler, Manuel Salto-Tellez, Sandra Van Schaeybroeck
CLINICAL CANCER RESEARCH
(2016)
Editorial Material
Urology & Nephrology
David J. J. Waugh
Article
Urology & Nephrology
Steven M. Walker, Laura A. Knight, Andrena M. McCavigan, Gemma E. Logan, Viktor Berge, Amir Sherif, Hardev Pandha, Anne Y. Warren, Catherine Davidson, Adam Uprichard, Jaine K. Blayney, Bethanie Price, Gera L. Jellema, Christopher J. Steele, Aud Svindland, Simon S. McDade, Christopher G. Eden, Chris Foster, Ian G. Mills, David E. Neal, Malcolm D. Mason, Elaine W. Kay, David J. Waugh, D. Paul Harkin, R. William Watson, Noel W. Clarke, Richard D. Kennedy
Article
Cell Biology
Christopher McCann, Nyree Crawford, Joanna Majkut, Caitriona Holohan, Chris W. D. Armstrong, Pamela J. Maxwell, Chee Wee Ong, Melissa J. LaBonte, Simon S. McDade, David J. Waugh, Daniel B. Longley
CELL DEATH & DISEASE
(2018)
Article
Oncology
Alan R. Gilmore, Matthew Alderdice, Kienan Savage, Paul G. O'Reilly, Aideen C. Roddy, Philip D. Dunne, Mark Lawler, Simon S. McDade, David J. Waugh, Darragh G. McArt
Article
Cell Biology
Diletta Di Mitri, Michela Mirenda, Jelena Vasilevska, Arianna Calcinotto, Nicolas Delaleu, Ajinkya Revandkar, Veronica Gil, Gunther Boysen, Marco Losa, Simone Mosole, Emiliano Pasquini, Rocco D'Antuono, Michela Masetti, Elena Zagato, Giovanna Chiorino, Paola Ostano, Andrea Rinaldi, Letizia Gnetti, Mariona Graupera, Ana Raquel Martins Figueiredo Fonseca, Ricardo Pereira Mestre, David Waugh, Simon Barry, Johann De Bono, Andrea Alimonti
Article
Oncology
Conor Hanna, Victoria L. Dunne, Steven M. Walker, Karl T. Butterworth, Nuala McCabe, David J. J. Waugh, Richard D. Kennedy, Kevin M. Prise
Summary: Prostate cancer is the most frequently diagnosed cancer in men, with the role of the PTEN gene being complex but important in its treatment. Studies suggest that in the absence of PTEN, combined treatment using radiotherapy and the ATM inhibitor KU-60019 has a greater therapeutic effect.
Article
Multidisciplinary Sciences
Francesca Amoroso, Kimberley Glass, Reema Singh, Francisco Liberal, Rebecca E. Steele, Sarah Maguire, Rohinton Tarapore, Joshua E. Allen, Sandra Van Schaeybroeck, Karl T. Butterworth, Kevin Prise, Joe M. O'Sullivan, Suneil Jain, David J. Waugh, Ian G. Mills
Summary: The study demonstrated that ONC201 can enhance the radiation response of prostate cancer cells by suppressing the expression of cell cycle and DNA repair factors.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Blossom Mak, Hui-Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate Mahon, Martin R. Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Andrew J. Hoy, Pan Du, Jianjun Yu, Shidong Jia, Anthony M. Joshua, David J. Waugh, Lisa M. Butler, Manish Kohli, Peter J. Meikle, Arun A. Azad, Lisa G. Horvath
Summary: This study assessed the association between circulating lipids, somatic genetic aberrations, and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The results revealed that certain genetic aberrations were associated with elevated circulating sphingolipids, and patients with both genetic and lipid abnormalities had worse prognosis. These findings may have implications for the selection of metabolic therapies.
Article
Oncology
Pamela J. Maxwell, Melanie McKechnie, Christopher W. Armstrong, Judith M. Manley, Chee Wee Ong, Jenny Worthington, Ian G. Mills, Daniel B. Longley, James P. Quigley, Amina Zoubeidi, Johann S. de Bono, Elena Deryugina, Melissa J. LaBonte, David J. J. Waugh
Summary: Inhibiting androgen signaling using androgen signaling inhibitors is the primary treatment for castrate-resistant prostate cancer. However, acquired resistance to androgen receptor-targeted therapy is a major challenge. This study found that enzalutamide induces hypoxia and angiogenesis, which may contribute to relapse. Concurrent inhibition of two hypoxia-induced factors can prolong tumor sensitivity to enzalutamide.
MOLECULAR CANCER RESEARCH
(2022)
Article
Genetics & Heredity
Ross G. Murphy, Aideen C. Roddy, Shambhavi Srivastava, Esther Baena, David J. Waugh, Joe M. O'Sullivan, Darragh G. McArt, Suneil Jain, Melissa J. LaBonte
NAR GENOMICS AND BIOINFORMATICS
(2020)
Article
Biochemistry & Molecular Biology
Chris W. D. Armstrong, Jonathan A. Coulter, Chee Wee Ong, Pamela J. Maxwell, Steven Walker, Karl T. Butterworth, Oksana Lyubomska, Silvia Berlingeri, Rebecca Gallagher, Joe M. O'Sullivan, Suneil Jain, Ian G. Mills, Kevin M. Prise, Robert G. Bristow, Melissa J. LaBonte, David J. J. Waugh
Review
Oncology
Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim N. Chi, Charlotte L. Bevan, Aki Shibakawa, Maarten J. IJzerman, Bram De Laere, Martijn Lolkema, David Lorente, Jun Luo, Niven Mehra, David Olmos, Howard Scher, Howard Soule, Nikolas H. Stoecklein, Leon W. M. M. Terstappen, David Waugh, Johann S. de Bono
EUROPEAN UROLOGY ONCOLOGY
(2018)
Article
Oncology
S. Jain, C. A. Lyons, S. M. Walker, S. McQuaid, S. O. Hynes, D. M. Mitchell, B. Pang, G. E. Logan, A. M. McCavigan, D. O'Rourke, D. G. McArt, S. S. McDade, I. G. Mills, K. M. Prise, L. A. Knight, C. J. Steele, P. W. Medlow, V. Berge, B. Katz, D. A. Loblaw, D. P. Harkin, J. A. James, J. M. O'Sullivan, R. D. Kennedy, D. J. Waugh
ANNALS OF ONCOLOGY
(2018)